Results 221 to 230 of about 5,297,540 (313)

Research trends in neoadjuvant therapy for esophageal cancer: a bibliometric and meta-analysis. [PDF]

Front Immunol
Wang H, Zhang J, Yang J, Chang H.
europepmc   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

Survival Outcomes in Patients With Locally Advanced NSCLC Converted to Resectable Disease by Neoadjuvant Therapy. [PDF]

In Vivo
Gulsen ED, Ismayilov R, Farzaliyeva A, Ramazanoglu MN, Oguz A, Kilic D, Akcali Z, Altundag O.   +7 more
europepmc   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Journal of Clinical Oncology, 2008
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie C. Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai   +12 more
semanticscholar   +1 more source

Two stable gut microbiome guilds predict liver tumor class and treatment responses

iMeta, EarlyView.
Gut microbiome alterations are linked to hepatocellular carcinoma (HCC), yet taxon‐based biomarkers often lack reproducibility. Using shotgun metagenomics from 120 resectable HCC (MT) and 76 benign hepatic tumor controls (BT), we reconstructed a stable interaction‐based Two Competing Guilds model (HCC‐TCG) comprising 142 genomes organized into two ...
Yang Liu, Zefan Zhang, Guojun Wu, Bowen Li, Linghua Wang, Jincheng Wang, Zixian Wei, Zhiyue Wang, Jinhua Yang, Kunyu Zhang, Tianqi Zhang, Xin Tao, Tao Chen, Jia Fan, Jian Zhou, Xinrong Yang, Liping Zhao, Yunwei Wei   +17 more
wiley   +1 more source

Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report. [PDF]

Front Oncol
Zhou J, Chen W, Wang J, Chen Z, Guo G, Yang T, Shen T.   +6 more
europepmc   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Laparoscopic Resection of Caudate Lobe Liver Tumors in Clinical Practice

iNew Medicine, EarlyView.
ABSTRACT The caudate lobe (Couinaud segment I), owing to its deep location in the posterosuperior liver, intimate encirclement by the inferior vena cava (IVC), and close adjacency to the hepatic hilum and major hepatic veins, presents a formidable anatomical challenge for resection.
Dingde Ye, Wenjie Zhang, Qiaoyu Liu, Beicheng Sun, Qingxiang Xu   +4 more
wiley   +1 more source